Atlas Trials

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Clinical trial NCT05404529 · COMPLETED

Trial details

NCT number
NCT05404529
Sponsor
Cerevel Therapeutics, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2022-04-29
Primary completion
2023-01-24
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.